|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EXTRACELLULAR MATRIX, CELL INTERACTIONS
Department of Molecular and Cellular Medicine, Texas A&M University System Health Science Center, College Station, Texas
Submitted 26 June 2008 ; accepted in final form 2 September 2008
| ABSTRACT |
|---|
|
|
|---|
angiogenesis; extracellular matrix; Notch; endothelial cell; sphingosine-1-phosphate; collagen
- and β-chains that combine to integrate the cytoskeleton with the ECM. The
2β1-integrin is an endothelial receptor for collagen type I (38, 129, 144) and has been shown to be required for angiogenesis in vivo and in vitro (33, 137), as have other integrins, including
1β1,
vβ3, and
5β1 (6, 12, 23, 31, 136, 137, 154). Angiogenic growth factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) are powerful proangiogenic stimuli, and multiple studies have documented the involvement of these growth factors and their receptors in mediating angiogenic events. Transgenic animals lacking VEGF and its receptors fail to form a functional vasculature (44, 46, 138), as do mice lacking the
v-integrin receptor (2) and the
5-integrin receptor (166), resulting in an embryonic lethal phenotype. In addition to angiogenic growth factors and integrins, sphingosine-1-phosphate (S1P) is a lysosphingolipid that has been reported to induce angiogenesis under various conditions (39, 58, 78, 79, 143) and is emerging as a novel target in anticancer therapies (96, 157). Cellular responses to S1P are mediated through activation of one or more of their five known high-affinity G protein-coupled receptors, S1P1–S1P5 (143). Knockout of the S1P1 receptor (also known as Edg1) in mice results in vascular defects, attributed to impairment of mural cell association with developing vasculature (85). Within wounded tissues, platelets deposit S1P and VEGF locally, while fibroblasts and other cells secrete bFGF (4, 14, 40, 99, 158, 167). Thus the coordination of S1P, growth factors, and integrin-ECM interaction is critical for mediating angiogenesis in wound healing. The in vitro system used here mimics a wound environment where S1P release would couple with local production of VEGF and FGF at the wound site to stimulate endothelial cell (EC) outgrowth and sprouting angiogenesis.
Because sprouting angiogenesis is a multistep process consisting of EC activation, basement membrane degradation, invasion and proliferation of ECs, lumen formation, and also stabilization, standard two-dimensional cell culture environments cannot completely reflect this dynamic process. One experimental approach to overcome this restriction is to use in vitro three-dimensional (3-D) models in which individual steps of angiogenesis can be reproduced (33, 37, 101, 103, 156). These studies not only allow for characterization of morphological changes, but also allow simultaneous monitoring of differential gene expression (7, 47, 52, 67). We have exploited one such model (5) in which S1P and angiogenic growth factors synergistically induce rapid EC sprouting and invasion in 3-D collagen matrices to mechanistically investigate the changes in gene expression that regulate the process. Data presented here indicate the coordinated regulation of molecules implicated in cell-cell and cell-matrix contacts, as well as in degradation and remodeling of ECM as endothelial invasion proceeds. To demonstrate a functional requirement for one such regulated gene, we knocked down a disintegrin and metalloproteinase with thrombospondin-type repeats-1 (ADAMTS1) using small interfering RNA (siRNA). Silencing of ADAMTS1 resulted in decreased invasion responses, indicating that ADAMTS1 is required for ECs to invade into 3-D collagen matrices. We also demonstrated that several components of signaling pathways, in particular, Wnt and Notch pathways, are systematically regulated. Activation of Notch signaling by enhanced expression of Delta-like 4 (DLL4) and Notch intracellular domains blocked EC invasion, while inhibition of Notch signaling by
-secretase inhibitor increased invasion density. Collectively, these data demonstrate that this system of EC invasion in 3-D collagen matrices closely resembles angiogenic events in vivo.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Gene profiling studies and data analysis. Three replicate experiments were performed, in which invading cells were collected at 0, 6, 12, and 18 h. Collagen matrices were digested with 50 µg collagenase (Sigma) each at 37°C for 5 min before being transferred into 8 ml of 1x M199 and centrifuged at 350 g for 5 min. RNA was extracted using an RNA extraction kit according to the manufacturer's instructions (Qiagen). RNA was eluted with 50 µl nuclease-free water (Ambion, Austin, TX). Total RNA was submitted to the Texas A&M University Center for Environmental and Rural Health for quality analysis using an Agilent Technologies 2100 Bioanalyzer. RNA was generated into biotin-labeled cRNA via a modified Eberwine RNA amplification protocol. The labeled cRNA was applied to the bioarray (GE Amersham CodeLink Human Whole Genome) and incubated for 18 h, then washed, stained, and scanned. The array images were processed using CodeLink's system software. Three replicates for each time point (0, 6, 12, and 18 h) were performed. Data were averaged and compared with time 0 data. Each data entry was analyzed by GeneSpring software at the Texas A&M Laboratory for Functional Genomics and considered for further analysis only if a 1.7-fold or greater elevation was observed.
Invasion quantification and image analysis. For quantifying the average numbers of invading cells per standardized field, conditioned media were removed and invasion samples were fixed with 3% glutaraldehyde (Sigma) in PBS overnight at 4°C. Cultures were stained with 0.1% toluidine blue (Sigma) containing 30% methanol (Fisher). Alternatively, cultures were fixed in 4% paraformaldehyde (Electron Microscopy Sciences) for 10 min and stained with 1.09 µM DAPI (Molecular Probes). Eyepieces mounted with a reticle displaying a 10 x 10 grid, which covers an area of 6.25 mm2, 1 mm2, and 0.25 mm2 at 4x, 10x, and 20x, respectively, were used for quantifying average numbers of invading cells per standardized field. For each data set, three to four separate fields from each treatment were recorded and averaged. For quantifying invasion distance and lumen diameter, photographs of invading cells were taken from a side view with an Olympus CKX41 microscope equipped with a Q color 3 Olympus camera. Measurements of invasion distance and lumen diameter were measured digitally using QCapture software (Olympus/Leeds), and pixel values were converted to micrometers. For immunofluorescence imaging, top-viewed photographs (whole mount) were taken under a Nikon Eclipse TE2000U fluorescence inverted microscope equipped with a CCD camera and MetaMorph software (Universal Imaging), and side-viewed photographs were captured by Stallion digital imaging workstation at the Image Analysis Laboratory, Texas A&M University.
Real-time PCR. An AccuScript High Fidelity 1st Strand cDNA Synthesis Kit (Stratagene) was used to prepare cDNA isolated from invading ECs. Primers were designed using Beacon Designer software such that amplicons were 180–220 bp. Primer sequences are listed in supplemental Table S1 (the online version of this article contains supplemental data). Primers were validated by real-time PCR using a fivefold serial dilution (125–0.04 ng/reaction) of untreated HUVEC cDNA and water as a nontemplate control, followed by agarose gel electrophoresis, to determine the amplification efficiency, specificity, and to rule out primer dimers. Reactions were analyzed on a Bio-Rad iCycler iQ Multicolor Real-Time PCR Detection system using iQ SYBR Green Supermix (Bio-Rad, Hercules, CA). Each real-time PCR reaction contained 0.5 ng/µl of cDNA and 400 nM of each primer in a 25-µl reaction volume. The reaction was initiated at 94°C for 1.5 min, followed by 40 two-step amplification cycles consisting of 15 s of denaturation at 95°C and 45 s of annealing/elongation at 60°C. A final dissociation stage was run to generate a melting curve for verification of amplicon specificity. Assays were performed in triplicate against three independent preparations of cDNA. For each reaction, a threshold cycle was observed in the exponential phase of amplification, and the quantification of relative expression levels was achieved using standard curves for both the target and a constitutively expressed gene, GADPH, whose expression changed <1.15-fold.
Immunoblotting and immunofluorescence.
For immunoblotting, cell lysates were prepared by transferring collagen gels containing invading ECs into boiling 1.5x Laemmli sample buffer containing 2% β-mercaptoethanol at 95°C for 10 min. Samples were separated using SDS-PAGE gels and transferred to polyvinylidene difluoride (Millipore). Antibodies against the following proteins were used for detection: claudin-5 (35-2500, Zymed), integrin-
2 (611016, BD Biosciences), integrin-
v (611012, BD Biosciences), ADAMTS1 (ab39194, Abcam, Cambridge, MA), Dkk2 (ab38594, Abcam), DAAM1 (M05, clone 5D3, Novus Biologicals, Littleton, CO), Delta-like 4 (NB600-892, Novus Biologicals), actin (CP01, Calbiochem), anti-FLAG M2 (F3165, Sigma), and G3PDH (ab8245, Abcam). For immunofluorescence, cell cultures were fixed in 4% paraformaldehyde and permeabilized in PBS containing 0.5% Triton X-100. Nonspecific binding was blocked by incubation with PBS containing 1% goat serum, 1% BSA, 0.2% sodium azide, and 0.1% Triton X-100. Following incubation with an anti-FLAG M2 monoclonal antibody (1:100 dilution; Sigma) for 2 h and FITC-conjugated goat anti-mouse IgG (1:50 dilution; Jackson ImmunoResearch) for 1 h, samples were mounted on glass slides with an antifading, aqueous mounting medium (Biomeda, Foster City, CA).
siRNA transfection. siGENOME SMARTpool human ADAMTS1, ADAMTS4, ADAM17, and GAPDH control siRNAs were obtained from Dharmacon (Lafayette, CO). Cells were seeded into 25-cm2 flasks at 40–50% confluency. The following day, cells were washed three times with serum- and antibiotic-free DMEM and transfected with 200 nM siRNA in 2.7 ml antibiotic-free DMEM using 20 µl siPORT Amine (Ambion). Flasks were aspirated and supplemented with antibiotic-free growth media at 8 h after transfection. This transfection procedure was repeated 2 days after the first transfection. After the second transfection, cells were fed and allowed to recover for 30 h before testing in invasion assays and verification of gene knockdown.
-Secretase inhibition.
Cells were resuspended at a density of 40,000 cells per 50 µl in M199 containing RSII and indicated concentrations of
-secretase inhibitor IX (565770, Calbiochem) or vehicle control (DMSO) and were incubated at 37°C with 5% CO2 for 20 min before being seeded on collagen gels with 100 nM S1P. For
-secretase inhibition, growth media contained RSII, ascorbic acid, VEGF, FGF-2, and indicated concentrations of
-secretase inhibitor. Cultures were fixed at 24 h to quantify invasion.
Plasmid constructs and gene transfer. Recombinant lentiviral vector encoding an enhanced green fluorescent protein (EGFP) was previously described (132) and was a kind gift from Dr. George E. Davis (Columbia, MO). Notch1 intracellular domain (N1ICD) (amino acids 1770-2556), Notch4 intracellular domain (N4ICD) (amino acids 1476-2003), and DLL4 were amplified by PCR from HUVEC cDNA and subcloned into pFLAG-CMV-5a (Sigma). The constructs were sequenced and tested for expression of the COOH-terminal FLAG-tagged N1ICD, N4ICD, and DLL4 in human embryonic kidney (HEK)-293 cells using anti-FLAG M2 antibodies (Sigma). FLAG-N1ICD, FLAG-N4ICD, and FLAG-DLL4 were amplified by PCR using pFLAG-CMV-5a clones as the templates and subcloned into pENTR4 (Invitrogen). Subsequently, genes with FLAG sequences were subcloned into pLenti6/V5-DEST using the Gateway system (Invitrogen). HUVECs were transduced with indicated constructs using the ViraPower Lentiviral Expression System (Invitrogen) according to the manufacturer's instructions. Invasion assays were conducted 3–7 days after infection.
| RESULTS |
|---|
|
|
|---|
|
Differential expression of cell adhesion molecules and ECM genes during EC invasion. Our data reveal that a series of genes that control endothelial cell-cell junctions and ECM recognition are systematically regulated during invasion. The invasion cultures consist of two populations of ECs, those that invade into the collagen matrix and those that stay behind. The decision to leave the monolayer and invade is likely associated with alterations in signaling between cell-cell contacts. Fitting with this idea, a set of genes that regulate tight junction (TJ) integrity was observed (supplemental Table S3). These downregulated genes include connexin 40 (CX40), connexin 45 (CX45), zona occludens 2 (ZO2), claudin5 (CLDN5), claudin11 (CLDN11), and claudin23 (CLDN23). Among them, the reduction of claudin11 transcript during invasion was confirmed by real-time PCR (Fig. 2A). TJs are intercellular ring structures that seal adjacent cells to one another. The TJ of ECs is mainly responsible for regulating paracellular permeability and maintaining planar cell polarity (139). TJs are composed of transmembrane proteins, which act as a fence to restrict the diffusion of lipids and proteins within the plane of the membrane. These data suggest that breakdown of TJ is associated with, and likely indispensable for, changes in cell polarity that occur during EC invasion.
|
2 (ITGA2), integrin-
v (ITGAV), and E-selectin (SELE) (supplemental Table S2). Protocadherin10 and protocadherin17, cadherin-related receptors belonging to the
2-protocadherin subfamily, not only exhibit cell-cell adhesion activities but also are believed to possess other functions, such as signal transduction and growth control (115). Our real-time PCR analysis revealed an increase in the expression levels of mRNA for PCDH10 and PCDH17 as ECs undergo invasion, increasing approximately two- and threefold, respectively (Fig. 2A). Moreover, ITGA2 and ITGAV were induced approximately threefold at the mRNA level (supplemental Table S2), and these data were confirmed by real-time PCR analysis (Fig. 2A). Another CAM gene with enhanced expression confirmed by real-time PCR analysis is E-selectin (Fig. 2A). Strikingly, also induced are some transmembrane receptors, which are involved in adhesion in some respects. These induced molecules are CUB domain-containing protein 1 (CDCP1), anthrax toxin receptor 2 (ANTXR2), anthrax toxin receptor 1 (ANTXR1), transcript variant 3, and podocalyxin-like (PODXL) protein. CDCP1, which represents a putative transmembrane protein containing three CUB domains in its extracellular part, is found to be overexpressed in human colon and lung cancer (133). Intriguingly, upregulation of ANTXR1 and ANTXR2 occurred during EC invasion. ANTXR1 is also known as a tumor-specific endothelial marker (20). ANTXR2 has been reported to bind collagen type IV and laminin directly (7), suggesting an important role for basement membrane matrix assembly. In addition, podocalyxin-like protein is a transmembrane sialomucin that is similar in structure to the well-characterized L-selectin ligand CD34 (69, 70). It has been reported to be a novel sinusoidal endothelial cell marker in hepatocellular carcinoma (22, 56). The induction of ANTXR2 and PODXL transcripts during invasion was verified by real-time PCR (Fig. 2A). Overall, these findings indicate that augmented expression of these CAM genes is consistent with stimulation by S1P and angiogenic growth factors. These factors would be expected to foster adequate adhesions with adjacent cells and ECM, as well as initiate diverse signaling events that mediate EC invasion.
In addition, multiple ECM genes are induced, such as secreted phosphoprotein 1 (SPP1), statherin (STATH), decorin (DCN), transcript variant B, laminin-
2 (LAMC2), collagen, type I,
2 (COL1A2), and nidogen 2 (NID2) (supplemental Table S2). The ECM serves as a scaffold in which mechanical forces are established among distal ECs, thereby providing guidance cues in the absence of cell-cell contact (34). Moreover, ECs require adhesions to ECM for migration, invasion, proliferation, and survival, all of which are critical for the process of angiogenesis. We used real-time PCR analysis to further confirm the increased expression of mRNA for secreted phosphoprotein 1, nidogen 2 and NADPH oxidase 4 (Fig. 2A). Secreted phosphoprotein SPP1, also known as osteopontin, is a matricellular protein that is upregulated during vascular injury and wound healing (48, 83). In addition, multiple studies have demonstrated upregulation of SPP1 in endometrial tissue where angiogenesis occurs during pregnancy (63–66). Nidogen 2 is a basement membrane-associated molecule that binds collagen I, collagen IV, perlecan, and laminin-1 (73, 93). Such induction of diverse ECM components in this system suggests an important role for the ECM as well as basement membrane components to precisely regulate the invasion process.
Induction of genes encoding ECM proteinases and their inhibitors.
Cumulative evidence has shown that an intricate balance between ECM proteinases and their inhibitors is critical for mediating diverse physiological events such as lineage decisions during embryogenesis, wound repair, cell migration, vascular stabilization, and survival (28, 132, 146, 159). Based on distinct domain structures, ECM proteolytic enzymes are divided into several protein families (148), many of which also display an augmented expression in our invasion system (supplemental Table S2). Microarray data indicated that ADAMTS1, a secreted metalloproteinase with thrombospondin type I motifs, was induced at the mRNA and protein level during invasion (Fig. 3, A and B). As shown in Fig. 3A and supplemental Table S2, another upregulated ADAMTSs is ADAMTS5, which is the major proteinase responsible for cartilage degradation in vivo and in vitro (49, 145). Interestingly,
2-macroglobulin, an endogenous inhibitor of ADAMTS5, was also induced (supplemental Table S2).
|
ADAMTS1 is required for EC invasion in 3-D collagen matrices. The data in Fig. 3 demonstrate that ADAMTS1 is upregulated at the mRNA and protein level. Because ADAMTS1 is known to associate with the plasma membrane and has been reported to promote collagen degradation (116), we next investigated whether ADAMTS1 is functionally required for EC invasion in collagen matrices. To accomplish this, ECs were treated with siRNA directed to G3PDH, ADAM17, ADAMTS1, and ADAMTS4. Western blot analyses of extracts collected from invading cultures revealed selective knockdown of ADAMTS1 and G3PDH controls with respective siRNAs (Fig. 4A). Photographs (side view) of invading cultures revealed that ECs treated with ADAMTS1 siRNA before being placed in invasion assays invaded shorter distances and contained larger lumens (Fig. 4B). ECs were tested in invasion assays in the presence and absence of phorbol ester (TPA), which enhanced invasion of ECs placed in 3-D matrices (72, 100, 102). Quantification of the invasion density revealed decreased numbers of invading cells with ADAMTS1 siRNA treatment (Fig. 4C). Invasion distance in ADAMTS1 siRNA-treated ECs was also significantly decreased compared with controls in the presence and absence of phorbol ester (Fig. 4D). Also, quantification of lumen diameter in invading structures revealed ECs treated with ADAMTS1 siRNA assembled into structures containing larger lumens (Fig. 4E). Thus, silencing of ADAMTS1 with siRNA confirms the functional involvement of ADAMTS1 in S1P and growth factor-stimulated EC invasion in 3-D collagen matrices.
|
|
Additional genes involved in cellular signaling include hedgehog-interacting protein (HIP) and NF-
B inhibitor-
(NFKBIa), both of which exhibit downregulation (Fig. 5C and supplemental Table S3). Hedgehog-interacting protein is a ligand for all three members of the hedgehog family, Sonic hedgehog (Shh), Indian hedgehog (Ihh), and Desert hedgehog (Dhh). HIP is expressed at high levels in ECs and can antagonize Shh responses in epithelial cells. Its expression is reduced on matrigel during chord formation, as well as in human cancers of the lung, liver, and gastrointestinal tract (108), which is consistent with downregulation in our model. Thus, HIP may function as an angiogenic suppressor, suggesting that activation of the hedgehog pathway may allow invasion to proceed. In addition, tumor invasion and angiogenesis are associated with NF-
B-mediated gene products, such as MMPs, uPA, and numerous chemokines (10, 43, 105), many of which are also induced during invasion. The signals that activate NF-
B during metastasis or angiogenesis remain incompletely understood, but they may be related to mutation of NF-
B inhibitor-
gene and enhanced degradation of NF-
B inhibitor-
protein (98, 162). Our findings suggest that a transcriptional regulation of NF-
B inhibitor-
may be involved in controlling EC invasion, along with modulation of Wnt, hedgehog, and Notch signaling pathways.
Notch signaling negatively regulates EC invasion.
Because several members of the Notch pathway were downregulated during EC invasion, we theorized that Notch inhibition would stimulate EC invasion. Treatment with
-secretase inhibitor, which prevents Notch processing, stimulated EC invasion in a dose-dependent manner (Fig. 6A). To confirm these data, we induced Notch activation in ECs using recombinant lentiviruses to express DLL4 and two constitutively active forms of Notch, Notch1 intracellular domain (N1ICD) and Notch4 intracellular domain (N4ICD), fused to a COOH-terminal Flag epitope, along with GFP control. Expression of DLL4 and activated Notch4 markedly blocked the EC invasion in the presence and absence of TPA, whereas activation of Notch1 modestly but significantly reduced invasion (Fig. 6B). In the presence of TPA, the ability of N4ICD and DLL4 to inhibit invasion was less pronounced, but N1ICD, N4ICD, and DLL4 all similarly reduced invasion compared with controls. Moreover, the invading structures formed by activated Notch4- or DLL4-expressing cells were markedly shorter and exhibited less branching than those derived from cells transduced with a GFP expression vector (Fig. 6, C and E), suggesting that activation of Notch signaling may alter the decision of EC for invading but also impair the ability to migrate in collagen matrices. Incorporation of COOH-terminal FLAG epitopes resulted in an ability to distinguish recombinantly expressed from endogenous proteins. We typically achieved lentiviral transduction efficiencies from 50% to 80% (data not shown). Figure 6D shows the expression of FLAG-tagged N1ICD, N4ICD, and DLL4 protein by immunoblotting. It is reported that Notch intracellular domain is targeted for degradation via proteasome pathway (106, 163). We have observed similar results in HUVECs, where treatment with proteosome inhibitors stabilized activated Notch protein expression (data not shown). Localization of Notch recombinant proteins within invading ECs was examined by immunofluorescence (top view Flag-FITC, Fig. 6E; supplemental Fig. S1). Photographs illustrate that GFP distributed throughout the cytoplasm, whereas N1ICD and N4ICD proteins localized to nucleus, which is typical of constitutively active Notch proteins (135, 147), and DLL4 protein localized on the plasma membrane (supplemental Fig. S1). Furthermore, GFP-expressing cells remained in the monolayer and invaded (Fig. 6E, top right). N1ICD- and N4ICD-positive cells, in contrast, did not invade and remained in the monolayer. DLL4-positive cells, like GFP, were detectable in invading cells as well as those that remained in the monolayer.
|
| DISCUSSION |
|---|
|
|
|---|
The three-dimensional model used in the present study incorporates the lysosphingolipid S1P, which is present in serum and is released by activated platelets. To our knowledge, this is the first study to investigate S1P- and growth factor-induced gene expression changes in primary endothelial cells. The assay system used here mimics a wound environment where S1P release would be coupled with local production of VEGF and bFGF to stimulate granulation tissue formation and new blood vessel growth. The combination of these factors not only stimulates EC invasion but likewise upregulates endothelial expression of the surface markers E-selectin and mucosal addressin cell adhesion molecule-1 (MADCAM1) that are involved in directing leukocyte extravasation (3, 8). Interestingly, NADPH oxidase 4 and cytochrome p450 (CYP450) are upregulated significantly at 6 h of invasion (Fig. 2A and supplemental Table S2), which suggests that this pathway may be initiated to activate the endothelium following exposure to S1P and angiogenic growth factors. CYP450 monooxygenases and NADPH oxidase can induce E-selectin, ICAM-1, and VCAM-1, whereas MADCAM1 induction may depend exclusively on CYP450-derived oxidants (130). Furthermore, multiple chemokines and chemokine receptor mRNA expression were observed to be significantly regulated with time. These are CCL1, CXCR, and CCRL1. Other relevant molecules include THY1, TNFSF11, TNFSF18, and COX-1. A recent study has shown that stable knockdown of one S1P receptor, S1P1, in ECs decreased the expression of several CAMs and influenced the inflammatory response of ECs (75). These data suggest that exposing the endothelium to S1P and angiogenic growth factors not only stimulates new blood vessel growth, but also alters EC expression of several inflammatory proteins that promote leukocyte extravasation and wound healing. These data are consistent with the well-known link between inflammatory cells and angiogenesis not only during tissue healing, but in many other contexts as well, including pregnancy (68, 149, 153), choroidal neovascularization (41, 51, 107, 127, 151), and tumor angiogenesis (26, 90, 113). These data also agree with the recognized role for S1P as an important inflammatory mediator that regulates lymphocyte egress, graft rejection, and recurrent multiple sclerosis (11, 35, 92, 123).
Cell-cell and cell-matrix contacts are integral in regulating angiogenesis. We have observed the downregulation of a set of genes associated with tight junctions, including CX40, CX45, ZO2, CLDN5, CLDN11, and CLDN23 (Fig. 2 and supplemental Table S2). Connexins have been recognized as tumor suppressors, whose expression is relevant to tumor progression in breast, lung, skin, liver, bladder, esophagus, and prostate cancers (95). Among members of connexin family, connexins 26 and 43 are the most extensively studied and found to be downregulated in various cancers and tumor angiogenesis (95). In a recent study, decreased expression of connexin 40 is detected in conditional phosphatase and tensin homolog (PTEN) knockout mice, which display enhanced tumorigenesis (53). Similarly, alterations in the expression levels of claudins (CLDNs) occur in various cancers. A thorough survey of CLDN expression in normal and neoplastic tissues indicates that the expression of most CLDN genes is decreased in cancers, while CLDN3, CLDN4, and CLDN7 are elevated in many malignancies (57). These data suggest that a decrease in endothelial tight junctions is a prerequisite for the onset of angiogenesis. In addition, our findings regarding the increased expression of integrin-
2 and -
v fits the well-defined roles for integrin receptors in sprouting angiogenesis (31). These integrins not only provide the adequate and necessary interactions with ECM but also emit intracellular signals to control cell shape and contractility. Integrin-
2β1 modulates VEGF-induced angiogenesis in vivo by a notable induction of actin polymerization through inhibition of PKA (cAMP-dependent protein kinase A) activity (136, 137, 160). Like
2β1 in collagen matrices (33),
vβ3 in combination with
5β1 control EC shape changes, including vacuolation and lumen formation in fibrin matrices (6). Therefore it seems plausible that multiple integrins may act together to create combinations of signals for neovascularization. Another intriguing finding in the present study is the induction of two members of
2-protocadherin gene family, PCDH10 and PCDH17 (Fig. 2). So far, little is known about the expression and function of these two protocadherins. However, it is clear that protocadherins may be more involved in intracellular signaling than in adhesive functions. One member of
2-protocadherin subfamily, PCDH8/PAPC, is found to interact with the Frizzled 7 receptor and can regulate the activity of the small GTPase, Rho and JNK, indicating a role in modulating the Wnt/planar cell polarity signaling pathway (94, 152). Perturbing PCDH8 activity in mice leads to the disruption of somite epithelialization during development (119), yet mice defective in PCDH8 not only possess normal skeleton but also are viable and fertile (165). These results suggest that functional redundancy among protocadherins exists.
ECM remodeling is crucial for all aspects of vascular biology and tumor progression. The ECM can be remodeled by biosynthesis and proteolytic degradation. We have demonstrated that the expression of several ECM genes is regulated during EC invasion (Fig. 2 and supplemental Table S2). Many ECM components identified in our microarray analysis were likewise upregulated in other studies using 3-D models of in vitro angiogenesis (7, 67) and proven as regulators of angiogenesis or vascular regression events (34, 142). Decorin, a proteoglycan that plays an important role in regulating collagen fibril organization (29), was induced in our invasion system (supplemental Table S2). Whereas decorin can inhibit EC migration and tube formation (30, 71), a line of evidence showed that decorin promotes endothelial tube formation in collagen gels (134). These conflicting results may be due to the complexity of ECM.
In addition to matrix molecules, a set of genes associated with the proteolytic processes of ECM was upregulated, including ADAMTS1, ADAMTS5, A2M, tPA, uPA, SERPINI1, MMP-10, CTSK, PRSS2, and LXN (Fig. 3 and supplemental Table S2). These molecules function as proteases and endogenous protease inhibitors. Cumulative evidence implies that the balance between proteases and their inhibitors is critical for angiogenesis. Most of these proteases are expressed in the extracellular milieu as inactive forms, which can be activated upon proteolytic cleavage by several families of proteases. To date, we have become aware that those proteases can target many non-ECM proteins, including growth factors, growth factor receptors, cell-associated molecules, and cytokines. Because several clinical trials using ECM proteases and their inhibitors as targets unfortunately appear inefficacious (25, 36, 111), a full understanding of the involvement and function of these molecules will be helpful for future treatments.
Gene expression profiling of the 3-D cultures revealed that S1P and angiogenic growth factor stimulation upregulated ADAMTS1 expression, which has been correlated with the highly vascularized ovulation cone in ovulation (15, 97, 120). Furthermore, targeted disruption of mouse ADAMTS1 gene results in abnormal adrenal medulla architecture without capillary formation, suggesting a role in angiogenesis (141). ADAMTS1 can cleave the proteoglycans aggrecan and versican (77, 128), which regulates ovulation (125). Inactivation of the gene by homologous recombination in mice resulted in decreased growth and renal defects (140). ADAMTS1 has been demonstrated to promote collagen degradation (116), fitting with our data that decreasing ADAMTS1 expression levels resulted in decreased invasion density and distances. ADAMTS1 was first cloned from a colon adenocarcinoma (76) and has been reported to be silenced by hypermethylation in colorectal tumors (84). Of note, the addition of recombinant ADAMTS1 to corneal pocket and chick chorioallantoic angiogenic assays (155) resulted in inhibition of angiogenic responses. ADAMTS1 can diminish VEGFR2 phosphorylation by binding and sequestering VEGF. This binding occurs via the COOH-terminal thrombospondin (TSP) motifs (87). Interestingly, ADAMTS1 is processed in this region to release the last two TSP domains. The cleavage event requires metalloproteinases, which may include MMP-2, MMP-8, and MMP-15 (122). It has been proposed that ADAMTS1 could function as an anti-angiogenic molecule through the release of TSP repeats (60) as do other proteins that harbor anti-angiogenic potential, such as collagen XVIII and plasminogen (17, 109, 110). Thus, presentation of ADAMTS1 on the cell surface or in soluble form may be critical for determining its mechanism of action. Thus far, we have been unable to detect cleavage or liberation of ADAMTS1 from the endothelial surface, consistent with its role as a collagenase during EC invasion.
Notch signaling has long been implicated in angiogenic events. It is well documented that the activation of Notch signaling plays an important role in vascular development (54, 59, 74, 124). Leong and colleagues (80) have described that expression of constitutively active Notch4 in human dermal microvascular endothelial cells inhibits endothelial sprouting and migration through collagen but not fibrinogen. In addition, Sainson and colleagues (126) have studied Notch inhibition in ECs resuspended in fibrin matrices. By using
-secretase inhibitors, a dominant-negative form of Notch1 or antisense for Notch1 and Notch4, Notch inhibition resulted in enlarged sprout diameter but not length through enhanced cell proliferation and extensive sprout branching. In contrast, another study indicated that constitutive activation of Notch1 enhanced network and cord formation of human iliac artery ECs (86). Here, we showed that several members of Notch signaling pathway, in particular target genes of Notch, were downregulated with time in our 3-D invasion system (Fig. 5 and supplemental Table S3), suggesting that Notch signaling is inhibited during EC invasion. Inhibition of Notch signaling using
-secretase inhibitor promoted increased numbers of invading ECs, and overexpression of a Notch ligand, DLL4, and two activated Notch receptors, N1ICD and N4ICD, all inhibited the EC invasion responses (Fig. 6). Even though all the above Notch data emerged from in vitro 3-D models, minor variations in the experimental conditions, such as matrices used, stimuli added, cell types involved, and the way Notch signal is manipulated, are present among those studies. Paradoxically, the activation of Notch signaling can exhibit both inhibitory effects on angiogenesis (55, 150, 161, 169) as well as promotive (27, 89, 112, 168). There are several variables that may account for these contradictory results. First, signals emitted from cis-interaction (cell-autonomous activation) could be different from those from trans-interaction (non-cell-autonomous manner) (50, 81). Next, different Notch intracellular domains may contribute to different transcriptional functions and target different genes for expression (42, 117). This, therefore, could be the reason that we observed differential effects between activated Notch1 and Notch4 on EC invasion. Another possible explanation is that a conventional two-dimensional cell culture environment fails to accurately reflect how Notch signaling is regulated during EC morphogenesis since sprouting angiogenesis is a 3-D multistep process. All of above may account for the similarities or discrepancies between our results and other's (80, 86, 126).
In conclusion, following stimulation by S1P and angiogenic growth factors, bFGF, and VEGF, gene expression profiles during EC invasion in 3-D collagen matrices were analyzed. Consistencies exist between our data and findings reported from other in vitro models and in vivo studies. The validation of gene expression in this study is focused on cell adhesion molecules, ECM, proteases/antiproteases, Wnt and Notch signaling pathways, and potential regulators of angiogenesis at mRNA or protein levels. In addition, EC invasion requires ADAMTS1 and is regulated following manipulation of Notch signaling. This knowledge will serve as a valuable resource for exploring molecular mechanisms underlying sprouting angiogenesis.
| GRANTS |
|---|
|
|
|---|
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
| REFERENCES |
|---|
|
|
|---|
2. Bader BL, Rayburn H, Crowley D, Hynes RO. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins. Cell 95: 507–519, 1998.[CrossRef][Web of Science][Medline]
3. Bargatze RF, Kurk S, Watts G, Kishimoto TK, Speer CA, Jutila MA. In vivo and in vitro functional examination of a conserved epitope of L- and E-selectin crucial for leukocyte-endothelial cell interactions. J Immunol 152: 5814–5825, 1994.[Abstract]
4. Battegay EJ. Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med 73: 333–346, 1995.[Web of Science][Medline]
5. Bayless KJ, Davis GE. Sphingosine-1-phosphate markedly induces matrix metalloproteinase and integrin-dependent human endothelial cell invasion and lumen formation in three-dimensional collagen and fibrin matrices. Biochem Biophys Res Commun 312: 903–913, 2003.[CrossRef][Web of Science][Medline]
6. Bayless KJ, Salazar R, Davis GE. RGD-dependent vacuolation and lumen formation observed during endothelial cell morphogenesis in three-dimensional fibrin matrices involves the alpha(v)beta(3) and alpha(5)beta(1) integrins. Am J Pathol 156: 1673–1683, 2000.
7. Bell SE, Mavila A, Salazar R, Bayless KJ, Kanagala S, Maxwell SA, Davis GE. Differential gene expression during capillary morphogenesis in 3D collagen matrices: regulated expression of genes involved in basement membrane matrix assembly, cell cycle progression, cellular differentiation and G-protein signaling. J Cell Sci 114: 2755–2773, 2001.
8. Berg EL, McEvoy LM, Berlin C, Bargatze RF, Butcher EC. L-selectin-mediated lymphocyte rolling on MAdCAM-1. Nature 366: 695–698, 1993.[CrossRef][Web of Science][Medline]
9. Berger P, Kozlov SV, Cinelli P, Kruger SR, Vogt L, Sonderegger P. Neuronal depolarization enhances the transcription of the neuronal serine protease inhibitor neuroserpin. Mol Cell Neurosci 14: 455–467, 1999.[CrossRef][Web of Science][Medline]
10. Bond M, Fabunmi RP, Baker AH, Newby AC. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappaB. FEBS Lett 435: 29–34, 1998.[CrossRef][Web of Science][Medline]
11. Brinkmann V, Cyster JG, Hla T. FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant 4: 1019–1025, 2004.[CrossRef][Web of Science][Medline]
12. Brooks PC, Strömblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, Quigley JP, Cheresh DA. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 85: 683–693, 1996.[CrossRef][Web of Science][Medline]
13. Brott BK, Sokol SY. Regulation of Wnt/LRP signaling by distinct domains of Dickkopf proteins. Mol Cell Biol 22: 6100–6110, 2002.
14. Browder T, Folkman J, Pirie-Shepherd S. The hemostatic system as a regulator of angiogenesis. J Biol Chem 275: 1521–1524, 2000.
15. Brown HM, Dunning KR, Robker RL, Pritchard M, Russell DL. Requirement for ADAMTS-1 in extracellular matrix remodeling during ovarian folliculogenesis and lymphangiogenesis. Dev Biol 300: 699–709, 2006.[CrossRef][Web of Science][Medline]
16. Brubaker KD, Vessella RL, True LD, Thomas R, Corey E. Cathepsin K mRNA and protein expression in prostate cancer progression. J Bone Miner Res 18: 222–230, 2003.[CrossRef][Web of Science][Medline]
17. Cao Y, Chen A, An SS, Ji RW, Davidson D, Llinas M. Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth. J Biol Chem 272: 22924–22928, 1997.
18. Carmeliet P. Angiogenesis in health and disease. Nat Med 9: 653–660, 2003.[CrossRef][Web of Science][Medline]
19. Carmeliet P. Manipulating angiogenesis in medicine. J Intern Med 255: 538–561, 2004.[CrossRef][Web of Science][Medline]
20. Carson-Walter EB, Watkins DN, Nanda A, Vogelstein B, Kinzler KW, St Croix B. Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res 61: 6649–6655, 2001.
21. Chang S, Young BD, Li S, Qi X, Richardson JA, Olson EN. Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell 126: 321–334, 2006.[CrossRef][Web of Science][Medline]
22. Chen X, Higgins J, Cheung ST, Li R, Mason V, Montgomery K, Fan ST, van de Rijn M, So S. Novel endothelial cell markers in hepatocellular carcinoma. Mod Pathol 17: 1198–1210, 2004.[CrossRef][Web of Science][Medline]
23. Cheresh DA, Smith JW, Cooper HM, Quaranta V. A novel vitronectin receptor integrin (alpha v beta x) is responsible for distinct adhesive properties of carcinoma cells. Cell 57: 59–69, 1989.[CrossRef][Web of Science][Medline]
24. Choong PF, Nadesapillai AP. Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis. Clin Orthop Relat Res 415: S46–S58, 2003.[CrossRef][Medline]
25. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295: 2387–2392, 2002.
26. Coussens LM, Werb Z. Inflammatory cells and cancer: think different! J Exp Med 193: F23–F26, 2001.[CrossRef][Medline]
27. Curry CL, Reed LL, Golde TE, Miele L, Nickoloff BJ, Foreman KE. Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells. Oncogene 24: 6333–6344, 2005.[Web of Science][Medline]
28. Danen EH, Sonnenberg A. Integrins in regulation of tissue development and function. J Pathol 201: 632–641, 2003.[CrossRef][Web of Science][Medline]
29. Danielson KG, Baribault H, Holmes DF, Graham H, Kadler KE, Iozzo RV. Targeted disruption of decorin leads to abnormal collagen fibril morphology and kin fragility. J Cell Biol 136: 729–743, 1997.
30. Davies Cde L, Melder RJ, Munn LL, Mouta-Carreira C, Jain RK, Boucher Y. Decorin inhibits endothelial migration and tube-like structure formation: role of thrombospondin-1. Microvasc Res 62: 26–42, 2001.[CrossRef][Web of Science][Medline]
31. Davis GE, Bayless KJ. An integrin and Rho GTPase-dependent pinocytic vacuole mechanism controls capillary lumen formation in collagen and fibrin matrices. Microcirculation 10: 27–44, 2003.[CrossRef][Web of Science][Medline]
33. Davis GE, Camarillo CW. An alpha 2 beta 1 integrin-dependent pinocytic mechanism involving intracellular vacuole formation and coalescence regulates capillary lumen and tube formation in three-dimensional collagen matrix. Exp Cell Res 224: 39–51, 1996.[CrossRef][Web of Science][Medline]
34. Davis GE, Senger DR. Endothelial extracellular matrix biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ Res 97: 1093–1107, 2005.
35. Dev KK, Mullershausen F, Mattes H, Kuhn RR, Bilbe G, Hoyer D, Mir A. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis. Pharmacol Ther 117: 77–93, 2008.[CrossRef][Web of Science][Medline]
36. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161–174, 2002.[Web of Science][Medline]
37. Egginton S, Gerritsen M. Lumen formation: in vivo versus in vitro observations. Microcirculation 10: 45–61, 2003.[CrossRef][Web of Science][Medline]
38. Elices MJ, Hemler ME. The human integrin VLA-2 is a collagen receptor on some cells and a collagen/laminin receptor on others. Proc Natl Acad Sci USA 86: 9906–9910, 1989.
39. English D, Brindley DN, Spiegel S, Garcia JG. Lipid mediators of angiogenesis and the signalling pathways they initiate. Biochim Biophys Acta 1582: 228–239, 2002.[Medline]
40. English D, Welch Z, Kovala AT, Harvey K, Volpert OV, Brindley DN, Garcia JG. Sphingosine 1-phosphate released from platelets during clotting accounts for the potent endothelial cell chemotactic activity of blood serum and provides a novel link between hemostasis and angiogenesis. FASEB J 14: 2255–2265, 2000.
41. Espinosa-Heidmann DG, Suner IJ, Hernandez EP, Monroy D, Csaky KG, Cousins SW. Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 44: 3586–3592, 2003.
42. Fan X, Mikolaenko I, Elhassan I, Ni X, Wang Y, Ball D, Brat DJ, Perry A, Eberhart CG. Notch1 and notch2 have opposite effects on embryonal brain tumor growth. Cancer Res 64: 7787–7793, 2004.
43. Farina AR, Tacconelli A, Vacca A, Maroder M, Gulino A, Mackay AR. Transcriptional up-regulation of matrix metalloproteinase-9 expression during spontaneous epithelial to neuroblast phenotype conversion by SK-N-SH neuroblastoma cells, involved in enhanced invasivity, depends upon GT-box and nuclear factor kappaB elements. Cell Growth Differ 10: 353–367, 1999.
44. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, Powell-Braxton L, Hillan KJ, Moore MW. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380: 439–442, 1996.[CrossRef][Web of Science][Medline]
45. Folkman J, D'Amore PA. Blood vessel formation: what is its molecular basis? Cell 87: 1153–1155, 1996.[CrossRef][Web of Science][Medline]
46. Fong GH, Rossant J, Gertsenstein M, Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376: 66–70, 1995.[CrossRef][Web of Science][Medline]
47. Gerritsen ME, Soriano R, Yang S, Zlot C, Ingle G, Toy K, Williams PM. Branching out: a molecular fingerprint of endothelial differentiation into tube-like structures generated by Affymetrix oligonucleotide arrays. Microcirculation 10: 63–81, 2003.[CrossRef][Web of Science][Medline]
48. Giachelli CM, Liaw L, Murry CE, Schwartz SM, Almeida M. Osteopontin expression in cardiovascular diseases. Ann NY Acad Sci 760: 109–126, 1995.[Web of Science][Medline]
49. Glasson SS, Askew R, Sheppard B, Carito B, Blanchet T, Ma HL, Flannery CR, Peluso D, Kanki K, Yang Z, Majumdar MK, Morris EA. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature 434: 644–648, 2005.[CrossRef][Web of Science][Medline]
50. Glittenberg M, Pitsouli C, Garvey C, Delidakis C, Bray S. Role of conserved intracellular motifs in Serrate signalling, cis-inhibition and endocytosis. EMBO J 25: 4697–4706, 2006.[CrossRef][Web of Science][Medline]
51. Grossniklaus HE, Ling JX, Wallace TM, Dithmar S, Lawson DH, Cohen C, Elner VM, Elner SG, Sternberg P Jr. Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol Vis 8: 119–126, 2002.[Web of Science][Medline]
52. Hahn CN, Su ZJ, Drogemuller CJ, Tsykin A, Waterman SR, Brautigan PJ, Yu S, Kremmidiotis G, Gardner A, Solomon PJ, Goodall GJ, Vadas MA, Gamble JR. Expression profiling reveals functionally important genes and coordinately regulated signaling pathway genes during in vitro angiogenesis. Physiol Genomics 22: 57–69, 2005.
53. Hamada K, Sasaki T, Koni PA, Natsui M, Kishimoto H, Sasaki J, Yajima N, Horie Y, Hasegawa G, Naito M, Miyazaki J, Suda T, Itoh H, Nakao K, Mak TW, Nakano T, Suzuki A. The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis. Genes Dev 19: 2054–2065, 2005.
54. Hellström M, Phng LK, Hofmann JJ, Wallgard E, Coultas L, Lindblom P, Alva J, Nilsson AK, Karlsson L, Gaiano N, Yoon K, Rossant J, Iruela-Arispe ML, Kalén M, Gerhardt H, Betsholtz C. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 445: 776–780, 2007.[CrossRef][Web of Science][Medline]
55. Henderson AM, Wang SJ, Taylor AC, Aitkenhead M, Hughes CC. The basic helix-loop-helix transcription factor HESR1 regulates endothelial cell tube formation. J Biol Chem 276: 6169–6176, 2001.
56. Heukamp LC, Fischer HP, Schirmacher P, Chen X, Breuhahn K, Nicolay C, Buttner R, Gutgemann I. Podocalyxin-like protein 1 expression in primary hepatic tumours and tumour-like lesions. Histopathology 49: 242–247, 2006.[CrossRef][Web of Science][Medline]
57. Hewitt KJ, Agarwal R, Morin PJ. The claudin gene family: expression in normal and neoplastic tissues. BMC Cancer 126: 186, 2006.
58. Hla T. Physiological and pathological actions of sphingosine 1-phosphate. Semin Cell Dev Biol 15: 513–520, 2004.[CrossRef][Web of Science][Medline]
59. Hofmann JJ, St Croix B. Notch signaling in blood vessels: who is talking to whom about what? Circ Res 100: 1556–1568, 2007.
60. Iruela-Arispe ML, Luque A, Lee N. Thrombospondin modules and angiogenesis. Int J Biochem Cell Biol 36: 1070–1078, 2004.[CrossRef][Web of Science][Medline]
61. Ishiguro H, Tsunoda T, Tanaka T, Fujii Y, Nakamura Y, Furukawa Y. Identification of AXUD1, a novel human gene induced by AXIN1 and its reduced expression in human carcinomas of the lung, liver, colon and kidney. Oncogene 20: 5062–5066, 2001.[CrossRef][Web of Science][Medline]
62. Jessani N, Humphrey M, McDonald WH, Niessen S, Masuda K, Gangadharan B, Yates JR, Mueller BM, Cravatt BF. Carcinoma and stromal enzyme activity profiles associated with breast tumor growth in vivo. Proc Natl Acad Sci USA 101: 13756–13761, 2004.
63. Johnson GA, Bazer FW, Jaeger LA, Ka H, Garlow JE, Pfarrer C, Spencer TE, Burghardt RC. Muc-1, integrin, and osteopontin expression during the implantation cascade in sheep. Biol Reprod 65: 820–828, 2001.
64. Johnson GA, Burghardt RC, Joyce MM, Spencer TE, Bazer FW, Pfarrer C, Gray CA. Osteopontin expression in uterine stroma indicates a decidualization-like differentiation during ovine pregnancy. Biol Reprod 68: 1951–1958, 2003.
65. Johnson GA, Spencer TE, Burghardt RC, Taylor KM, Gray CA, Bazer FW. Progesterone modulation of osteopontin gene expression in the ovine uterus. Biol Reprod 62: 1315–1321, 2000.
66. Joyce MM, González JF, Lewis S, Woldesenbet S, Burghardt RC, Newton GR, Johnson GA. Caprine uterine and placental osteopontin expression is distinct among epitheliochorial implanting species. Placenta 26: 160–170, 2005.[CrossRef][Web of Science][Medline]
67. Kahn J, Mehraban F, Ingle G, Xin X, Bryant JE, Vehar G, Schoenfeld J, Grimaldi CJ, Peale F, Draksharapu A, Lewin DA, Gerritsen ME. Gene expression profiling in an in vitro model of angiogenesis. Am J Pathol 156: 1887–1900, 2000.
68. Kayisli UA, Guzeloglu-Kayisli O, Arici A. Endocrine-immune interactions in human endometrium. Ann NY Acad Sci 1034: 50–63, 2004.[CrossRef][Web of Science][Medline]
69. Kershaw DB, Thomas PE, Wharram BL, Goyal M, Wiggins JE, Whiteside CI, Wiggins RC. Molecular cloning, expression, and characterization of podocalyxin-like protein 1 from rabbit as a transmembrane protein of glomerular podocytes and vascular endothelium. J Biol Chem 270: 29439–29446, 1995.
70. Kershaw DB, Wiggins JE, Wharram BL, Wiggins RC. Assignment of the human podocalyxin-like protein (PODXL) gene to 7q32-q33. Genomics 45: 239–240, 1997.[CrossRef][Web of Science][Medline]
71. Kinsella MG, Fischer JW, Mason DP, Wight TN. Retrovirally mediated expression of decorin by macrovascular endothelial cells. Effects on cellular migration and fibronectin fibrillogenesis in vitro. J Biol Chem 275: 13924–13932, 2000.
72. Koh W, Mahan RD, Davis GE. Cdc42- and Rac1-mediated endothelial lumen formation requires Pak2, Pak4 and Par3, and PKC-dependent signaling. J Cell Sci 121: 989–1001, 2008.
73. Kohfeldt E, Sasaki T, Gohring W, Timpl R. Nidogen-2: a new basement membrane protein with diverse binding properties. J Mol Biol 282: 99–109, 1998.[CrossRef][Web of Science][Medline]
74. Krebs LT, Xue Y, Norton CR, Shutter JR, Maguire M, Sundberg JP, Gallahan D, Closson V, Kitajewski J, Callahan R, Smith GH, Stark KL, Gridley T. Notch signaling is essential for vascular morphogenesis in mice. Genes Dev 14: 1343–1352, 2000.
75. Krump-Konvalinkova V, Yasuda S, Rubic T, Makarova N, Mages J, Erl W, Vosseler C, Kirkpatrick CJ, Tigyi G, Siess W. Stable knock-down of the sphingosine 1-phosphate receptor S1P1 influences multiple functions of human endothelial cells. Arterioscler Thromb Vasc Biol 25: 546–552, 2005.
76. Kuno K, Kanada N, Nakashima E, Fujiki F, Ichimura F, Matsushima K. Molecular cloning of a gene encoding a new type of metalloproteinase-disintegrin family protein with thrombospondin motifs as an inflammation associated gene. J Biol Chem 272: 556–562, 1997.
77. Kuno K, Okada Y, Kawashima H, Nakamura H, Miyasaka M, Ohno H, Matsushima K. ADAMTS-1 cleaves a cartilage proteoglycan, aggrecan. FEBS Lett 478: 241–245, 2000.[CrossRef][Web of Science][Medline]
78. Langlois S, Gingras D, Béliveau R. Membrane type 1-matrix metalloproteinase (MT1-MMP) cooperates with sphingosine 1-phosphate to induce endothelial cell migration and morphogenic differentiation. Blood 103: 3020–3028, 2004.
79. Lee OH, Kim YM, Lee YM, Moon EJ, Lee DJ, Kim JH, Kim KW, Kwon YG. Sphingosine 1-phosphate induces angiogenesis: its angiogenic action and signaling mechanism in human umbilical vein endothelial cells. Biochem Biophys Res Commun 264: 743–750, 1999.[CrossRef][Web of Science][Medline]
80. Leong KG, Hu X, Li L, Noseda M, Larrivée B, Hull C, Hood L, Wong F, Karsan A. Activated Notch4 inhibits angiogenesis: role of beta 1-integrin activation. Mol Cell Biol 22: 2830–2841, 2002.
81. Li Y, Baker NE. The roles of cis-inactivation by Notch ligands and of neuralized during eye and bristle patterning in Drosophila. BMC Dev Biol 4: 5, 2004.[CrossRef][Medline]
82. Liang Y, Jansen M, Aronow B, Geiger H, Van Zant G. The quantitative trait gene latexin influences the size of the hematopoietic stem cell population in mice. Nat Genet 39: 178–188, 2007.[CrossRef][Web of Science][Medline]
83. Liaw L, Birk DE, Ballas CB, Whitsitt JS, Davidson JM, Hogan BL. Altered wound healing in mice lacking a functional osteopontin gene (spp1). J Clin Invest 101: 1468–1478, 1998.[Web of Science][Medline]
84. Lind GE, Kleivi K, Meling GI, Teixeira MR, Thiis-Evensen E, Rognum TO, Lothe RA. ADAMTS1, CRABP1, and NR3C1 identified as epigenetically deregulated genes in colorectal tumorigenesis. Cell Oncol 28: 259–272, 2006.[Web of Science][Medline]
85. Liu Y, Wada R, Yamashita T, Mi Y, Deng CX, Hobson JP, Rosenfeldt HM, Nava VE, Chae SS, Lee MJ, Liu CH, Hla T, Spiegel S, Proia RL. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Invest 106: 951–961, 2000.[Web of Science][Medline]
86. Liu ZJ, Shirakawa T, Li Y, Soma A, Oka M, Dotto GP, Fairman RM, Velazquez OC, Herlyn M. Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. Mol Cell Biol 23: 14–25, 2003.
87. Luque A, Carpizo DR, Iruela-Arispe ML. ADAMTS1/METH1 inhibits endothelial cell proliferation by direct binding and sequestration of VEGF165. J Biol Chem 278: 23656–23665, 2003.
88. Maciag T, Cerundolo J, Ilsley S, Kelley PR, Forand R. An endothelial cell growth factor from bovine hypothalamus: identification and partial characterization. Proc Natl Acad Sci USA 76: 5674–5678, 1979.
89. Mailhos C, Modlich U, Lewis J, Harris A, Bicknell R, Ish-Horowicz D. Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis. Differentiation 69: 135–144, 2001.[CrossRef][Web of Science][Medline]
90. Makitie T, Summanen P, Tarkkanen A, Kivela T. Tumor-infiltrating macrophages (CD68+ cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci 42: 1414–1421, 2001.
91. Mao B, Niehrs C. Kremen2 modulates Dickkopf2 activity during Wnt/LRP6 signaling. Gene 302: 179–183, 2003.[CrossRef][Web of Science][Medline]
92. Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, Allende ML, Proia RL, Cyster JG. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427: 355–360, 2004.[CrossRef][Web of Science][Medline]
93. Mayer U, Kohfeldt E, Timpl R. Structural and genetic analysis of laminin-nidogen interaction. Ann NY Acad Sci 857: 130–142, 1998.[CrossRef][Web of Science][Medline]
94. Medina A, Swain RK, Kuerner KM, Steinbeisser H. Xenopus paraxial protocadherin has signaling functions and is involved in tissue separation. EMBO J 23: 3249–3258, 2004.[CrossRef][Web of Science][Medline]
95. Mesnil M, Crespin S, Avanzo JL, Zaidan-Dagli M. Defective gap junctional intercellular communication in the carcinogenic process. Biochim Biophys Acta 1719: 125–145, 2005.[Medline]
96. Milstien S, Spiegel S. Targeting sphingosine-1-phosphate: a novel avenue for cancer therapeutics. Cancer Cell 9: 148–150, 2006.[CrossRef][Web of Science][Medline]
97. Mittaz L, Russell DL, Wilson T, Brasted M, Tkalcevic J, Salamonsen LA, Hertzog PJ, Pritchard MA. Adamts-1 is essential for the development and function of the urogenital system. Biol Reprod 70: 1096–1105, 2004.
98. Miyamoto S, Chiao PJ, Verma IM. Enhanced I kappa B alpha degradation is responsible for constitutive NF-kappa B activity in mature murine B-cell lines. Mol Cell Biol 14: 3276–3282, 1994.
99. Möhle R, Green D, Moore MA, Nachman RL, Rafii S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA 94: 663–668, 1997.
100. Montesano R, Orci L. Tumor-promoting phorbol esters induce angiogenesis in vitro. Cell 42: 469–477, 1985.[CrossRef][Web of Science][Medline]
101. Montesano R, Pepper MS, Vassalli JD, Orci L. Modulation of angiogenesis in vitro. EXS 61: 129–136, 1992.[Medline]
102. Montesano R, Pepper MS, Vassalli JD, Orci L. Phorbol ester induces cultured endothelial cells to invade a fibrin matrix in the presence of fibrinolytic inhibitors. J Cell Physiol 132: 509–516, 1987.[CrossRef][Web of Science][Medline]
103. Nicosia RF, Villaschi S. Autoregulation of angiogenesis by cells of the vessel wall. Int Rev Cytol 185: 1–43, 1999.[Web of Science][Medline]
104. Nie J, McGill MA, Dermer M, Dho SE, Wolting CD, McGlade CJ. LNX functions as a RING type E3 ubiquitin ligase that targets the cell fate determinant Numb for ubiquitin-dependent degradation. EMBO J 21: 93–102, 2002.[CrossRef][Web of Science][Medline]
105. Novak U, Cocks BG, Hamilton JA. A labile repressor acts through the NFkB-like binding sites of the human urokinase gene. Nucleic Acids Res 19: 3389–3393, 1991.
106. Oberg C, Li J, Pauley A, Wolf E, Gurney M, Lendahl U. The Notch intracellular domain is ubiquitinated and negatively regulated by the mammalian Sel-10 homolog. J Biol Chem 276: 35847–35853, 2001.
107. Oh H, Takagi H, Takagi C, Suzuma K, Otani A, Ishida K, Matsumura M, Ogura Y, Honda Y. The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes. Invest Ophthalmol Vis Sci 40: 1891–1898, 1999.
108. Olsen CL, Hsu PP, Glienke J, Rubanyi GM, Brooks AR. Hedgehog-interacting protein is highly expressed in endothelial cells but down-regulated during angiogenesis and in several human tumors. BMC Cancer 44: 43, 2004.
109. O'Reilly MS. Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth. EXS 79: 273–294, 1997.[Medline]
110. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Cao Y, Moses M, Lane WS, Sage EH, Folkman J. Angiostatin: a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth. Cold Spring Harb Symp Quant Biol 59: 471–482, 1994.
111. Overall CM, Kleifeld O. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 6: 227–239, 2006.[CrossRef][Web of Science][Medline]
112. Patel NS, Li JL, Generali D, Poulsom R, Cranston DW, Harris AL. Up-regulation of Delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res 65: 8690–8697, 2005.
113. Porta C, Subhra Kumar B, Larghi P, Rubino L, Mancino A, Sica A. Tumor promotion by tumor-associated macrophages. Adv Exp Med Biol 604: 67–86, 2007.[Web of Science][Medline]
114. Rakic JM, Maillard C, Jost M, Bajou K, Masson V, Devy L, Lambert V, Foidart JM, Noël A. Role of plasminogen activator-plasmin system in tumor angiogenesis. Cell Mol Life Sci 60: 463–473, 2003.[CrossRef][Web of Science][Medline]
115. Redies C, Vanhalst K, Roy F. delta-Protocadherins: unique structures and functions. Cell Mol Life Sci 62: 2840–2852, 2005.[CrossRef][Web of Science][Medline]
116. Rehn AP, Birch MA, Karlstrom E, Wendel M, Lind T. ADAMTS-1 increases the three-dimensional growth of osteoblasts through type I collagen processing. Bone 41: 231–238, 2007.[CrossRef][Web of Science][Medline]
117. Reizis B, Leder P. Direct induction of T lymphocyte-specific gene expression by the mammalian Notch signaling pathway. Genes Dev 16: 295–300, 2002.
118. Reuning U, Magdolen V, Wilhelm O, Fischer K, Lutz V, Graeff H, Schmitt M. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review). Int J Oncol 13: 893–906, 1998.[Web of Science][Medline]
119. Rhee J, Takahashi Y, Saga Y, Wilson-Rawls J, Rawls A. The protocadherin papc is involved in the organization of the epithelium along the segmental border during mouse somitogenesis. Dev Biol 254: 248–261, 2003.[CrossRef][Web of Science][Medline]
120. Richards JS, Hernandez-Gonzalez I, Gonzalez-Robayna I, Teuling E, Lo Y, Boerboom D, Falender AE, Doyle KH, LeBaron RG, Thompson V, Sandy JD. Regulated expression of ADAMTS family members in follicles and cumulus oocyte complexes: evidence for specific and redundant patterns during ovulation. Biol Reprod 72: 1241–1255, 2005.
121. Robitaille J, MacDonald ML, Kaykas A, Sheldahl LC, Zeisler J, Dubé MP, Zhang LH, Singaraja RR, Guernsey DL, Zheng B, Siebert LF, Hoskin-Mott A, Trese MT, Pimstone SN, Shastry BS, Moon RT, Hayden MR, Goldberg YP, Samuels ME. Mutant frizzled-4 disrupts retinal angiogenesis in familial exudative vitreoretinopathy. Nat Genet 32: 326–330, 2002.[CrossRef][Web of Science][Medline]
122. Rodriguez-Manzaneque JC, Westling J, Thai SN, Luque A, Knauper V, Murphy G, Sandy JD, Iruela-Arispe ML. ADAMTS1 cleaves aggrecan at multiple sites and is differentially inhibited by metalloproteinase inhibitors. Biochem Biophys Res Commun 293: 501–508, 2002.[CrossRef][Web of Science][Medline]
123. Rosen H, Goetzl EJ. Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat Rev Immunol 5: 560–570, 2005.[CrossRef][Web of Science][Medline]
124. Rossant J, Hirashima M. Vascular development and patterning: making the right choices. Curr Opin Genet Dev 13: 408–412, 2003.[CrossRef][Web of Science][Medline]
125. Russell DL, Doyle KM, Ochsner SA, Sandy JD, Richards JS. Processing and localization of ADAMTS-1 and proteolytic cleavage of versican during cumulus matrix expansion and ovulation. J Biol Chem 278: 42330–42339, 2003.
126. Sainson RC, Aoto J, Nakatsu MN, Holderfield M, Conn E, Koller E, Hughes CC. Cell-autonomous notch signaling regulates endothelial cell branching and proliferation during vascular tubulogenesis. FASEB J 19: 1027–1029, 2005.
127. Sakurai E, Anand A, Ambati BK, van Rooijen N, Ambati J. Macrophage depletion inhibits experimental choroidal neovascularization.Invest Ophthalmol Vis Sci 44: 3578–3585, 2003.
128. Sandy JD, Westling J, Kenagy RD, Iruela-Arispe ML, Verscharen C, Rodriguez-Mazaneque JC, Zimmermann DR, Lemire JM, Fischer JW, Wight TN, Clowes AW. Versican V1 proteolysis in human aorta in vivo occurs at the Glu441-Ala442 bond, a site that is cleaved by recombinant ADAMTS-1 and ADAMTS-4. J Biol Chem 276: 13372–13378, 2001.
129. Santoro SA, Zutter MM. The alpha 2 beta 1 integrin: a collagen receptor on platelets and other cells. Thromb Haemost 74: 813–821, 1995.[Web of Science][Medline]
130. Sasaki M, Ostanin D, Elrod JW, Oshima T, Jordan P, Itoh M, Joh T, Minagar A, Alexander JS. TNF-
-induced endothelial cell adhesion molecule expression is cytochrome P-450 monooxygenase dependent. Am J Physiol Cell Physiol 284: C422–C428, 2003.
131. Saunders WB, Bayless KJ, Davis GE. MMP-1 activation by serine proteases and MMP-10 induces human capillary tubular network collapse and regression in 3D collagen matrices. J Cell Sci 118: 2325–2340, 2005.
132. Saunders WB, Bohnsack BL, Faske JB, Anthis NJ, Bayless KJ, Hirschi KK, Davis GE. Coregulation of vascular tube stabilization by endothelial cell TIMP-2 and pericyte TIMP-3. J Cell Biol 175: 179–191, 2006.
133. Scherl-Mostageer M, Sommergruber W, Abseher R, Hauptmann R, Ambros P, Schweifer N. Identification of a novel gene, CDCP1, overexpressed in human colorectal cancer. Oncogene 20: 4402–4408, 2001.[CrossRef][Web of Science][Medline]
134. Schönherr E, O'Connell BC, Schittny J, Robenek H, Fastermann D, Fisher LW, Plenz G, Vischer P, Young MF, Kresse H. Paracrine or virus-mediated induction of decorin expression by endothelial cells contributes to tube formation and prevention of apoptosis in collagen lattices. Eur J Cell Biol 78: 44–55, 1999.[Web of Science][Medline]
135. Schroeter EH, Kisslinger JA, Kopan R. Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature 393: 382–386, 1998.[CrossRef][Web of Science][Medline]
136. Senger DR, Claffey KP, Benes JE, Perruzzi CA, Sergiou AP, Detmar M. Angiogenesis promoted by vascular endothelial growth factor: regulation through alpha1beta1 and alpha2beta1 integrins. Proc Natl Acad Sci USA 94: 13612–13617, 1997.
137. Senger DR, Perruzzi CA, Streit M, Koteliansky VE, de Fougerolles AR, Detmar M. The alpha(1)beta(1) and alpha(2)beta(1) integrins provide critical support for vascular endothelial growth factor signaling, endothelial cell migration, and tumor angiogenesis. Am J Pathol 160: 195–204, 2002.
138. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, Schuh AC. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376: 62–66, 1995.[CrossRef][Web of Science][Medline]
139. Shin K, Fogg VC, Margolis B. Tight junctions and cell polarity. Annu Rev Cell Dev Biol 22: 207–235, 2006.[CrossRef][Web of Science][Medline]
140. Shindo T, Kurihara H, Kuno K, Yokoyama H, Wada T, Kurihara Y, Imai T, Wang Y, Ogata M, Nishimatsu H, Moriyama N, Oh-hashi Y, Morita H, Ishikawa T, Nagai R, Yazaki Y, Matsushima K. ADAMTS-1: a metalloproteinase-disintegrin essential for normal growth, fertility, and organ morphology and function. J Clin Invest 105: 1345–1352, 2000.[Web of Science][Medline]
141. Shindo T, Kurihara H, Kuno K, Yokoyama H, Wada T, Kurihara Y, Imai T, Wang Y, Ogata M, Nishimatsu H, Moriyama N, Oh-hashi Y, Morita H, Ishikawa T, Nagai R, Yazaki Y, Matsushima K. ADAMTS-1: a metalloproteinase-disintegrin essential for normal growth, fertility, and organ morphology and function. J Clin Invest 105: 1345–1352, 2000.[Web of Science][Medline]
142. Sottile J. Regulation of angiogenesis by extracellular matrix. Biochim Biophys Acta 1654: 13–22, 2004.[Medline]
143. Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol 4: 397–407, 2003.[CrossRef][Web of Science][Medline]
144. Staatz WD, Walsh JJ, Pexton T, Santoro SA. The alpha 2 beta 1 integrin cell surface collagen receptor binds to the alpha 1 (I)-CB3 peptide of collagen. J Biol Chem 265: 4778–4781, 1990.
145. Stanton H, Rogerson FM, East CJ, Golub SB, Lawlor KE, Meeker CT, Little CB, Last K, Farmer PJ, Campbell IK, Fourie AM, Fosang AJ. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature 434: 648–652, 2005.[CrossRef][Web of Science][Medline]
146. Streuli C. Extracellular matrix remodelling and cellular differentiation. Curr Opin Cell Biol 11: 634–640, 1999.[CrossRef][Web of Science][Medline]
147. Struhl G, Adachi A. Nuclear access and action of notch in vivo. Cell 93: 649–660, 1998.[CrossRef][Web of Science][Medline]
148. Tang BL. ADAMTS: a novel family of extracellular matrix proteases. Int J Biochem Cell Biol 33: 33–44, 2001.[CrossRef][Web of Science][Medline]
149. Tayade C, Fang Y, Croy BA. A review of gene expression in porcine endometrial lymphocytes, endothelium and trophoblast during pregnancy success and failure. J Reprod Dev 53: 455–463, 2007.[CrossRef][Web of Science][Medline]
150. Taylor KL, Henderson AM, Hughes CC. Notch activation during endothelial cell network formation in vitro targets the basic HLH transcription factor HESR-1 and downregulates VEGFR-2/KDR expression. Microvasc Res 64: 372–383, 2002.[CrossRef][Web of Science][Medline]
151. Tsutsumi C, Sonoda KH, Egashira K, Qiao H, Hisatomi T, Nakao S, Ishibashi M, Charo IF, Sakamoto T, Murata T, Ishibashi T. The critical role of ocular-infiltrating macrophages in the development of choroidal neovascularization. J Leukoc Biol 74: 25–32, 2003.
152. Unterseher F, Hefele JA, Giehl K, De Robertis EM, Wedlich D, Schambony A. Paraxial protocadherin coordinates cell polarity during convergent extension via Rho A and JNK. EMBO J 23: 3259–3269, 2004.[CrossRef][Web of Science][Medline]
153. Van den Heuvel MJ, Chantakru S, Xuemei X, Evans SS, Tekpetey F, Mote PA, Clarke CL, Croy BA. Trafficking of circulating pro-NK cells to the decidualizing uterus: regulatory mechanisms in the mouse and human. Immunol Invest 34: 273–293, 2005.[CrossRef][Web of Science][Medline]
154. Varner JA, Emerson DA, Juliano RL. Integrin alpha 5 beta 1 expression negatively regulates cell growth: reversal by attachment to fibronectin. Mol Biol Cell 6: 725–740, 1995.[Abstract]
155. Vazquez F, Hastings G, Ortega MA, Lane TF, Oikemus S, Lombardo M, Iruela-Arispe ML. METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity. J Biol Chem 274: 23349–23357, 1999.
156. Vernon RB, Sage EH. Between molecules and morphology. Extracellular matrix and creation of vascular form. Am J Pathol 147: 873–883, 1995.[Abstract]
157. Visentin B, Vekich JA, Sibbald BJ, Cavalli AL, Moreno KM, Matteo RG, Garland WA, Lu Y, Yu S, Hall HS, Kundra V, Mills GB, Sabbadini RA. Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 9: 225–238, 2006.[CrossRef][Web of Science][Medline]
158. Wartiovaara U, Salven P, Mikkola H, Lassila R, Kaukonen J, Joukov V, Orpana A, Ristimäki A, Heikinheimo M, Joensuu H, Alitalo K, Palotie A. Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thromb Haemost 80: 171–175, 1998.[Web of Science][Medline]
159. Werb Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell 91: 439–442, 1997.[CrossRef][Web of Science][Medline]
160. Whelan MC, Senger DR. Collagen I initiates endothelial cell morphogenesis by inducing actin polymerization through suppression of cyclic AMP and protein kinase A. J Biol Chem 278: 327–334, 2003.
161. Williams CK, Li JL, Murga M, Harris AL, Tosato G. Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood 107: 931–939, 2005.[CrossRef][Web of Science][Medline]
162. Wood KM, Roff M, Hay RT. Defective IkappaBalpha in Hodgkin cell lines with constitutively active NF-kappaB. Oncogene 16: 2131–2139, 1998.[CrossRef][Web of Science][Medline]
163. Wu G, Lyapina S, Das I, Li J, Gurney M, Pauley A, Chui I, Deshaies RJ, Kitajewski J. SEL-10 is an inhibitor of notch signaling that targets notch for ubiquitin-mediated protein degradation. Mol Cell Biol 21: 7403–7415, 2001.
164. Wu W, Glinka A, Delius H, Niehrs C. Mutual antagonism between dickkopf1 and dickkopf2 regulates Wnt/beta-catenin signalling. Curr Biol 10: 1611–1614, 2000.[CrossRef][Web of Science][Medline]
165. Yamamoto A, Kemp C, Bachiller D, Geissert D, De Robertis EM. Mouse paraxial protocadherin is expressed in trunk mesoderm and is not essential for mouse development. Genesis 27: 49–57, 2000.[CrossRef][Web of Science][Medline]
166. Yang JT, Rayburn H, Hynes RO. Embryonic mesodermal defects in alpha 5 integrin-deficient mice. Development 119: 1093–1105, 1993.[Abstract]
167. Yatomi Y, Ohmori T, Rile G, Kazama F, Okamoto H, Sano T, Satoh K, Kume S, Tigyi G, Igarashi Y, Ozaki Y. Sphingosine 1-phosphate as a major bioactive lysophospholipid that is released from platelets and interacts with endothelial cells. Blood 96: 3431–3438, 2000.
168. Zeng Q, Li S, Chepeha DB, Giordano TJ, Li J, Zhang H, Polverini PJ, Nor J, Kitajewski J, Wang CY. Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Cancer Cell 8: 13–23, 2005.[CrossRef][Web of Science][Medline]
169. Zimrin AB, Pepper MS, McMahon GA, Nguyen F, Montesano R, Maciag T. An antisense oligonucleotide to the notch ligand jagged enhances fibroblast growth factor-induced angiogenesis in vitro. J Biol Chem 271: 32499–32502, 1996.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |